Alvotech (ALVO) Q1 2026 earnings summary

Executive summary

• Advanced FDA resubmission, inspection readiness, and global commercial expansion, including three biosimilar launches in Europe and other markets.

• Facility upgrades and quality system enhancements led to a temporary production slowdown, impacting revenues and EBITDA, but recovery is expected as operations normalize.

• Strategic manufacturing agreement with FUJIFILM Biotechnologies to expand and diversify U.S. supply, with supply expected in H2 2027.

• Strong demand for biosimilars, especially Humira in the U.S., and pipeline progress including Entyvio and high-dose Eylea.

• Commercial presence in over 90 countries, transitioning from R&D to a global commercial biosimilar company.

Financial highlights

• Q1 2026 revenues were $106 million, down 20% year-over-year due to facility improvements and production slowdown.

• Gross margin improved to 57%, up 6 percentage points year-over-year; adjusted EBITDA was $24.4 million (23% margin).

• Product revenues were $51 million, with key contributions from biosimilars to HUMIRA (AVT02) and STELARA (AVT04).

• Licensing and other revenue increased to $55 million, up 139% year-over-year, due to milestone recognition timing.

• Cash at hand at quarter-end was $64 million; operating cash flow negative $25 million, mainly due to working capital and inventory build.

Outlook and guidance

• Full-year 2026 revenue guidance: $650–$700 million, representing double-digit growth over 2025.

• Adjusted EBITDA expected between $180–$220 million.

• Q4 2026 anticipated to be the strongest quarter; positive free cash flow targeted for Q4 2026.

• Lower end of guidance assumes no new U.S. product launches in 2026; U.S. approval for pending BLAs anticipated by late 2026.

• 2027 expected to deliver strong year-on-year growth, driven by expanded portfolio and increased manufacturing output.